Lamellar ichthyosis — designated LI, a clinically and genetically heterogeneous group of autosomal recessive congenital ichthyoses characterized by the universal involvement of the body surface with large, dark, plate-like scales over a normal or mildly erythematous skin surface, distinguishable from the erythrodermic congenital ichthyosiform erythroderma (CIE) by the predominance of scaling over erythema and by specific underlying molecular defects — encompasses mutations in at least a dozen genes encoding enzymes and structural proteins of the epidermal cornification pathway, with the most frequently implicated genes including TGM1 (encoding transglutaminase 1, responsible for approximately 30–40% of LI cases, the enzyme that crosslinks loricrin, involucrin, and other cornified envelope proteins into the insoluble structural scaffold of the stratum corneum), ABCA12 (the ABCA12 lipid transporter at the milder end of its mutation spectrum, with less severe ABCA12 hypomorphic mutations causing LI rather than the more severe harlequin ichthyosis phenotype), ALOX12B and ALOXE3 (encoding arachidonate 12-lipoxygenase 12R-type and hydroperoxide isomerase — two enzymes of the hepoxilin pathway generating lipid mediators essential for tight junction assembly in the granular layer), CYP4F22 (encoding a cytochrome P450 enzyme involved in ceramide metabolism), NIPAL4/ichthyin, STS (steroid sulfatase — though STS mutations more commonly cause X-linked ichthyosis rather than true autosomal recessive LI), and multiple additional rare gene variants whose pathogenic contributions have been elucidated by the genomic revolution in ichthyosis classification; the clinical phenotype — large, quadrangular, brown-gray scales distributed over the entire body surface including the face, scalp, and flexures, with variable ectropion, variable palmoplantar keratoderma, and variable involvement of the ears — presents at birth as a collodion baby (the collodion membrane, a taut, parchment-like, shiny membrane covering the entire newborn that cracks and peels over the first weeks of life revealing the underlying ichthyotic phenotype) and evolves over the first weeks and months of life to the characteristic lamellar scaling phenotype; the pathophysiology reflects the absence or dysfunction of the cornification machinery (transglutaminase 1 crosslinking, lipid matrix assembly, ceramide generation, tight junction-lipid coupling) that produces a stratum corneum with defective mechanical integrity and barrier function — generating the characteristic scaling through accelerated corneocyte shedding combined with defective corneocyte cohesion, the thermoregulatory dysfunction through the thick scale that prevents eccrine sweat secretion from reaching the skin surface (anhidrosis or hypohidrosis causing heat intolerance and dangerous hyperthermia), and the pruritus through the inflammatory signals generated by the disrupted barrier; management involves lifelong intensive topical therapy (keratolytics — urea, lactic acid, salicylic acid; emollients — petrolatum, mineral oil, ceramide-containing formulations), systemic retinoid therapy for moderate-to-severe cases (acitretin, with the same pregnancy prevention program requirements as for other ichthyoses treated with systemic retinoids), genetic testing for molecular subtyping that informs prognosis and guides clinical trial eligibility, and the genetic counseling for the autosomal recessive inheritance pattern affecting reproductive planning.
Lamellar ichthyosis technology platforms — encompassing the dermatology specialty platforms coordinating the intensive topical and systemic therapy regimens for a condition requiring lifelong daily skin care work, the genetic testing platforms where TGM1, ALOX12B, ALOXE3, CYP4F22, NIPAL4, and panel sequencing identify the underlying molecular subtype, the neonatal platforms managing the collodion baby presentation in the NICU, the pharmacy platforms managing acitretin including the pregnancy prevention program, the thermoregulatory monitoring platforms tracking hyperthermia risk and heat intolerance management, the ophthalmology platforms managing ectropion where present, the patient registry and multidisciplinary coordination platforms supporting the LI patient community, and the clinical trial platforms where novel topical and systemic therapies targeting specific LI molecular subtypes are evaluated — must maintain the availability and performance standards required by the neonatal collodion management urgency, the genetic subtyping that determines treatment approach, the lifelong retinoid therapy monitoring obligations, and the thermoregulation safety demands that define modern lamellar ichthyosis management. This guide explains why lamellar ichthyosis tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the collodion neonatal management, molecular subtyping, retinoid therapy, thermoregulation surveillance, and lifelong dermatological coordination that define modern LI care.
Why Lamellar Ichthyosis Tech Platforms Require Specialized Monitoring Attention
Lamellar ichthyosis management is defined by several uniquely challenging genetic dermatological management considerations: the collodion baby neonatal management imperative — newborns with lamellar ichthyosis frequently present as collodion babies, with the taut collodion membrane creating risks of ectropion, feeding difficulties, respiratory restriction from chest wall stiffness, and infection risk through cracks in the membrane, requiring NICU management with high-humidity incubation, topical emollient to soften and facilitate membrane shedding, ophthalmological management, and the ongoing uncertainty about which collodion baby will evolve to which ichthyosis subtype as the membrane sheds; the thermoregulatory emergency risk — the thick scale over lamellar ichthyosis skin impairs eccrine sweat delivery to the skin surface, producing anhidrosis or hypohidrosis that makes LI patients unable to thermoregulate by sweating during physical activity, hot weather, or febrile illness, creating risk of severe heat stroke that can be fatal if platforms coordinating thermoregulation monitoring and emergency heat protocols are unavailable; the molecular subtyping clinical significance — TGM1-mutant LI responds differently to retinoid therapy than ALOX12B-mutant or CYP4F22-mutant LI, making the molecular subtype a determinant of therapy selection and clinical trial eligibility, and making genetic testing platform availability critical to optimized treatment; and the acitretin management complexity — the systemic retinoid therapy used for moderate-to-severe LI carries the same extensive Category X pregnancy prevention, liver function, lipid, and bone density monitoring obligations as for other ichthyoses managed with systemic retinoids.
TGM1, ALOX12B, ALOXE3, CYP4F22, and LI gene panel testing platforms guide therapy selection. Molecular subtyping determines which patients are likely to respond to topical TGM1 enzyme replacement strategies, which subtypes have specific clinical trial eligibility, and what the recurrence risk profile is for autosomal recessive carrier counseling. Monitor genetic testing platforms at 1-minute intervals during laboratory hours.
Collodion baby NICU coordination platforms must support 24/7 neonatal management. The collodion membrane creates acute neonatal risks requiring continuous multidisciplinary platform availability from birth through membrane shedding. Monitor NICU coordination platforms at 1-minute intervals, 24/7.
Thermoregulation monitoring platforms protect against heat stroke. The anhidrosis of LI creates dangerous hyperthermia risk during hot weather, physical activity, and febrile illness — thermoregulation platforms coordinating school accommodations, activity restrictions, heat event protocols, and emergency cooling procedures require continuous availability during the months when heat stroke risk is highest. Monitor thermoregulation platforms at 1-minute intervals during relevant periods.
Acitretin management platforms coordinate retinoid therapy and mandatory pregnancy prevention. The Category X teratogen management obligations — monthly pregnancy testing, dual contraception, 3-year post-discontinuation contraception monitoring — alongside liver function, lipid, and bone density monitoring require reliable clinical and pharmacy platform availability. Monitor retinoid management platforms at 1-minute intervals during operational hours.
Ophthalmology platforms manage ectropion complications where present. For the subset of LI patients with significant ectropion — more common in TGM1-mutant and some ALOX-mutant subtypes — continuous ophthalmological monitoring for corneal exposure complications is required. Monitor ophthalmology platforms at 1-minute intervals during clinical hours.
What to Monitor on a Lamellar Ichthyosis Tech Platform
Genetic Testing — LI Gene Panel Molecular Subtyping
Monitor genetic testing referral records (clinical LI presentation documentation — large quadrangular scaling, collodion baby history, ectropion, palmoplantar keratoderma, hypohidrosis/anhidrosis; family history of autosomal recessive inheritance; comprehensive LI gene panel order including TGM1, ABCA12, ALOX12B, ALOXE3, CYP4F22, NIPAL4, and additional LI genes), LI panel sequencing records (biallelic variant identification in relevant LI genes; variant classification — pathogenic, likely pathogenic, variant of uncertain significance; prediction of functional consequence — null versus hypomorphic alleles), molecular subtype confirmation records (TGM1-mutant LI versus ALOX-mutant versus CYP4F22-mutant versus NIPAL4-mutant — subtype designation with clinical and therapeutic implications), parental carrier testing records, and clinical trial eligibility assessment records (molecular subtype matched to open clinical trials — TGM1 enzyme replacement topical therapy trials, systemic and topical investigational agents) at 1-minute intervals during laboratory hours. Alert immediately — LI gene panel testing platform failures during the evaluation of a 3-year-old with severe lamellar scaling delay the TGM1 versus ALOX12B subtype identification that determines whether the child is a candidate for topical TGM1 gene therapy trials or ALOX pathway-targeted investigational agents, and delays the formal molecular confirmation needed for parental carrier counseling regarding future pregnancies.
Neonatal ICU — Collodion Baby Management
Monitor neonatal admission and collodion membrane management records (NICU admission documentation, humidified incubator specifications, humidity target monitoring, topical emollient application schedule for membrane softening and desquamation facilitation — white petrolatum or equivalent applied multiple times daily), collodion membrane complication surveillance records (ectropion development and severity, perioral tightness and feeding impairment, digit constriction bands from tight membrane — constriction band monitoring with doppler if digit circulation compromised, ophthalmological intervention timing), infection surveillance records (membrane crack cultures, systemic infection parameters — temperature, WBC, CRP, blood culture), and collodion-to-ichthyosis transition records (membrane shedding timeline documentation, emerging ichthyosis phenotype characterization as scaling pattern develops, first dermatology assessment as the post-collodion LI phenotype becomes assessable) at 1-minute intervals, 24/7. Alert immediately — NICU coordination platform failures during the first week of life for a collodion baby who is developing ectropion, has membrane cracks with suspected infection, and whose digit circulation requires monitoring for constriction band compromise leave the nursing and specialist teams without the integrated coordination platform needed to synchronize simultaneous ophthalmic, infectious disease, and vascular management interventions.
Thermoregulation — Hyperthermia Risk Management
Monitor thermoregulation risk assessment records (anhidrosis or hypohidrosis documentation from sweat testing — quantitative sudomotor axon reflex test or starch iodide sweat test, exercise-induced hyperthermia history, geographic heat exposure risk), school and activity accommodation records (school health plans documenting LI-specific accommodations — air-conditioned environments, avoidance of outdoor activity during peak heat, cool water spray availability, rest breaks, recognition of overheating by teachers and coaches), heat event protocol records (emergency cooling protocol documentation — cool water immersion, wet towel cooling, fan cooling, when to activate emergency medical services for a heat stroke event), and summer and seasonal monitoring records (temperature alert thresholds for weather conditions triggering enhanced monitoring and activity restriction for the LI patient) at 1-minute intervals during clinical hours and extended hours during summer months. Alert immediately — thermoregulation monitoring platform failures during an August heat wave when a 10-year-old LI patient attends a summer camp without air conditioning leave the family, camp staff, and pediatric dermatologist without the coordinated heat management protocol that prevents the potentially fatal heat stroke to which anhidrotic LI patients are highly vulnerable.
Dermatology — Topical and Systemic Therapy Coordination
Monitor topical therapy regimen records (keratolytic product type, strength, and application schedule — urea 10–40%, lactic acid 5–12%, salicylic acid 3–6%; emollient type and quantity prescribed; application technique instructions; scale debridement approach and frequency), acitretin prescription and dispensing records (dose documentation, dose adjustment history, clinical response tracking — scaling severity, pruritus, quality of life), skin care supply management records (prescription keratolytic quantities, emollient quantities, specialty product availability — confirmation that required products are in stock and obtainable for the LI patient whose daily skin care requires substantial quantities of emollient), and clinical photography and disease severity documentation records (standardized photography for treatment response assessment, EASI/SCORAD-equivalent LI severity scoring, interval change documentation) at 1-minute intervals during clinical hours. Alert immediately — dermatology platform failures that prevent the attending dermatologist from accessing a 16-year-old's current topical regimen, acitretin dose, most recent severity score, and clinical photograph series during an urgent visit for a marked worsening of scaling and pruritus leave the provider without the baseline documentation needed to determine whether the worsening represents a drug interaction, adherence issue, or disease progression requiring acitretin dose adjustment.
Acitretin Pregnancy Prevention Program
Monitor mandatory pregnancy testing records (monthly urine pregnancy test before each acitretin refill for female patients of childbearing potential, pregnancy test to dispensing linkage, test result date and result), dual contraception counseling records (documentation of two effective contraceptive methods in use simultaneously, method documentation, annual re-counseling), teratogenicity counseling records (Category X teratogenicity and the 3-year post-discontinuation contraception obligation due to adipose tissue storage of the acitretin metabolite etretinate), and post-discontinuation monitoring records (contraception documentation for 36 months after last dose, interval pregnancy testing after discontinuation) at 1-minute intervals during clinical and pharmacy hours. Alert immediately — acitretin pregnancy prevention program platform failures prevent the pregnancy test to dispensing gate that must be confirmed before each monthly dispensing for a female LI patient.
Ophthalmology — Ectropion Management (Where Present)
Monitor ectropion assessment records (severity grading, corneal exposure area, scleral show, lagophthalmos during sleep — assessment at each ophthalmology visit), corneal surveillance records (fluorescein staining for epithelial defects, slit-lamp corneal clarity assessment, corneal sensitivity testing, punctate epitheliopathy documentation), lubricant adherence records (artificial tear frequency, lubricating ointment — especially nocturnal application for lagophthalmos-related exposure during sleep, moisture chamber), and surgical referral records (ectropion surgical correction indications — failed medical management with progressive corneal exposure keratopathy or cosmetically severe ectropion limiting quality of life) at 1-minute intervals during clinical hours. Alert immediately — ophthalmology platform failures for an LI patient with known TGM1-mutant lamellar ichthyosis and moderate bilateral ectropion prevent the dermatologist from reviewing the most recent slit-lamp findings when the patient presents with a new ocular complaint, potentially delaying the identification of a corneal ulcer requiring urgent ophthalmic management.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. Lamellar ichthyosis management coordinates across neonatal intensive care (collodion management), genetics and rare disease (LI subtype molecular diagnosis), dermatology (topical and systemic therapy), pharmacy and specialty pharmacy (acitretin pregnancy prevention program), ophthalmology (ectropion and corneal management), pediatric health systems (school accommodation and thermoregulation planning), and rare disease patient community support — authentication failures block every member of the care team required to execute the lifelong multidisciplinary management that defines modern LI care.
SSL Certificates
Monitor SSL certificate expiry across all genetic testing platforms, NICU coordination portals, dermatology management systems, acitretin pregnancy prevention program platforms, ophthalmology monitoring platforms, thermoregulation protocol portals, and rare disease coordination platforms. Certificate errors disrupt neonatal emergency coordination, retinoid therapy compliance, and thermoregulation emergency protocols.
HIPAA and Ultra-Rare Disease Patient Privacy Considerations
Lamellar ichthyosis technology platforms handle sensitive PHI for a patient population where individual identification risk from diagnosis-linked data is elevated — LI is rare enough that patients in many communities may be one of very few individuals with the diagnosis, and the visually apparent nature of the skin condition means that clinical photography records, used to document treatment response, contain particularly identifiable information. Records include TGM1, ALOX12B, CYP4F22, and other LI gene biallelic molecular variant data with autosomal recessive inheritance implications, acitretin pregnancy prevention program compliance documentation, collodion baby NICU records, and thermoregulation risk documentation.
The heritable nature of LI gene mutations creates genetic information privacy obligations under GINA in addition to HIPAA Privacy and Security Rule requirements. For thermoregulation risk management platforms — where platform unavailability during a heat event leaves an LI patient without access to the emergency cooling protocol that could prevent fatal heat stroke — availability monitoring provides operational documentation relevant to both HIPAA Security Rule and patient safety compliance frameworks.
Alerting Strategy for Lamellar Ichthyosis Tech Platforms
Immediate 24/7 alerting for NICU coordination platforms: Collodion baby management in lamellar ichthyosis requires continuous neonatal multidisciplinary coordination without any acceptable window of disruption.
Immediate laboratory-hours alerting for LI gene panel testing platforms: TGM1, ALOX12B, ALOXE3, CYP4F22, NIPAL4, and multi-gene panel sequencing. These must be available during the molecular subtyping that determines therapy selection and clinical trial eligibility.
Immediate clinical-hours alerting for thermoregulation monitoring platforms: Hyperthermia risk from anhidrosis in lamellar ichthyosis creates potentially fatal heat stroke risk, particularly during summer months, making thermoregulation protocol platforms a patient safety-critical system.
Immediate clinical-hours alerting for acitretin management platforms: Pregnancy prevention program, liver function, lipid, and bone density monitoring cannot fail during clinical and pharmacy operational hours.
Immediate clinical-hours alerting for dermatology coordination platforms: Topical regimen, disease severity tracking, and clinical photography must be available for every dermatology visit for an LI patient.
Sustained-failure alert (10–15 minutes): Rare disease patient registry, clinical trial enrollment platforms, and long-term quality-of-life monitoring.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms LI platform availability from the geographies where lamellar ichthyosis specialty dermatology programs, LI gene panel molecular testing laboratories, and acitretin specialty pharmacy networks operate.
Status Page for Lamellar Ichthyosis Care Team Communication
A real-time status page gives NICU teams managing collodion babies, dermatologists coordinating lifelong topical and systemic LI therapy, molecular genetic laboratories running LI gene panels, specialty pharmacists managing acitretin pregnancy prevention program compliance, ophthalmologists monitoring ectropion complications, school health coordinators implementing LI thermoregulation accommodations, and rare disease patient coordinators supporting registry enrollment immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in collodion baby NICU management protocols, acitretin dispensing procedures, and thermoregulation emergency protocol documentation.
Vigilmon Setup for Lamellar Ichthyosis Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | NICU coordination (collodion baby management) | 1 min | Slack + PagerDuty (24/7) | | LI gene panel sequencing (TGM1, ALOX12B, ALOXE3, CYP4F22, NIPAL4) | 1 min | Slack + PagerDuty (lab hours) | | Genetic counseling and molecular subtype reporting | 1 min | Slack + PagerDuty (lab hours) | | Thermoregulation risk assessment and heat protocol | 1 min | Slack + PagerDuty (clinical hours, extended summer coverage) | | Acitretin prescription and dispensing | 1 min | Slack + PagerDuty (clinical hours) | | Acitretin pregnancy prevention program | 1 min | Slack + PagerDuty (clinical hours) | | Liver function and lipid monitoring (acitretin) | 1 min | Slack + PagerDuty (lab hours) | | Dermatology skin care and disease severity tracking | 1 min | Slack + PagerDuty (clinical hours) | | Ophthalmology — ectropion and corneal exposure | 1 min | Slack + PagerDuty (clinical hours) | | School accommodation and thermoregulation planning | 2 min | Slack (business hours) | | Clinical trial eligibility and enrollment | 2 min | Slack (business hours) | | Rare disease patient registry | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure NICU coordination platform with 24/7 immediate alerting for collodion baby management
- Add LI gene panel testing platforms with immediate laboratory-hours alerting
- Configure genetic counseling and molecular subtype reporting with immediate laboratory-hours alerting
- Add thermoregulation risk management and heat event protocol platforms with immediate clinical-hours alerting, extended to evenings and weekends during summer months
- Configure acitretin prescription and dispensing platforms with immediate clinical-hours alerting
- Add acitretin pregnancy prevention program platforms with immediate clinical-hours alerting
- Configure liver function and lipid monitoring platforms with immediate laboratory-hours alerting
- Add dermatology skin care and disease severity tracking platforms with immediate clinical-hours alerting
- Configure ophthalmology ectropion and corneal exposure platforms with immediate clinical-hours alerting
- Add school accommodation and thermoregulation planning platforms with sustained-failure alerting during business hours
- Configure clinical trial eligibility and enrollment platforms with sustained-failure alerting
- Add rare disease patient registry with sustained-failure alerting
- Enable SSL certificate monitoring across all genetic testing, NICU, dermatology, pharmacy, ophthalmology, and registry platforms
- Add the status page URL to collodion baby NICU protocols, acitretin pregnancy prevention documentation, and thermoregulation emergency plans
Conclusion
Lamellar ichthyosis technology platforms are embedded in clinical decisions where thermoregulation monitoring platform availability — when a 13-year-old with TGM1-mutant lamellar ichthyosis and documented anhidrosis is at a summer soccer camp during a heat advisory, and the school and camp health protocol platforms must be accessible to the camp nurse who is monitoring this child's core temperature during outdoor activities, to the parents who have registered the child for a camp with air-conditioned rest facilities based on the LI heat intolerance management plan documented in the platform, and to the pediatric dermatologist who has been called by the parents because the child is feeling dizzy and confused after 45 minutes of outdoor activity in 95-degree heat — cannot be disrupted by thermoregulation monitoring platform failures that leave the camp nurse without the LI heat protocol, the parents without the emergency cooling instructions, and the dermatologist without the documented anhidrosis severity assessment needed to advise whether immediate emergency medical services activation is warranted, because in anhidrotic lamellar ichthyosis the heat stroke that kills healthy children only when core temperature exceeds 40.5°C can occur at much lower external temperatures and with much shorter heat exposures than clinicians without LI experience would expect; where LI gene panel testing platform availability during the molecular evaluation of a 6-month-old with severe large-scale lamellar ichthyosis — when the TGM1 versus ALOX12B versus CYP4F22 molecular subtype determination will determine whether the child's family should be referred to a TGM1 enzyme replacement gene therapy trial whose enrollment requires biallelic TGM1 null mutations, and whether the autosomal recessive inheritance pattern informs the 25% recurrence risk counseling that the parents need before making reproductive decisions — cannot be disrupted by gene panel platform failures that delay the molecular result while the family is waiting for the diagnosis that frames every subsequent management decision; where acitretin pregnancy prevention program platform availability for an 18-year-old female LI patient — when the specialty pharmacy must verify this month's negative pregnancy test and dual contraception documentation before dispensing the next cycle of the Category X retinoid that has given this patient the best skin control and quality of life she has experienced in her 18-year history with lamellar ichthyosis — cannot be disrupted by specialty pharmacy platform failures that prevent the mandatory pregnancy prevention gate execution; and where NICU collodion baby management platform availability in the first days of life — when a newborn is in the neonatal intensive care unit under humidified incubation with multiple daily emollient applications, ophthalmological management for developing ectropion, and infection surveillance for membrane crack colonization — cannot be disrupted by NICU coordination platform failures that leave the care team without the integrated multidisciplinary management platform that coordinates the multiple simultaneous interventions needed to safely navigate the collodion-to-lamellar-ichthyosis transition. A thermoregulation protocol platform unavailable during a heat emergency for an anhidrotic LI patient, an LI gene panel testing platform interrupted when molecular subtyping determines clinical trial eligibility and reproductive counseling, an acitretin pregnancy prevention program platform failing for a female patient on a Category X teratogen, a NICU collodion baby platform unavailable during the highest-risk neonatal period — these are not IT incidents. They are clinical disruptions in the management of a lifelong severe genetic skin disorder whose anhidrosis-driven heat stroke risk, molecular subtype-guided therapy selection, mandatory retinoid teratogenicity management, and neonatal collodion presentation make thermoregulation protocol availability, LI gene panel testing continuity, acitretin pregnancy prevention compliance, and collodion NICU coordination platform reliability the operational foundations on which lamellar ichthyosis patient safety depends.
Uptime monitoring gives lamellar ichthyosis tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to dermatology specialty centers, molecular genetics laboratories, specialty pharmacies, neonatal intensive care units, and compliance auditors that platform operational reliability matches the heat stroke prevention urgency, molecular subtype-guided therapy precision, retinoid teratogenicity management obligations, and neonatal collodion management demands of modern LI care.
Start monitoring your lamellar ichthyosis care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #lamellar #ichthyosis #TGM1 #transglutaminase #ALOX12B #ALOXE3 #CYP4F22 #NIPAL4 #collodion #baby #NICU #acitretin #retinoid #anhidrosis #thermoregulation #heat #stroke #ectropion #rare #genetic #skin #disorder #HIPAA #healthtech #digitalhealth #uptime #sre